Affiliation:
1. Department of Clinical Chemistry Sestre milosrdnice University Hospital Center, Zagreb , Croatia
2. Department of Biochemistry and Molecular Biology , University of Zagreb Faculty of Pharmacy and Biochemistry Croatia
Abstract
Abstract
Direct oral anticoagulants (DOACs) represent a new generation of drugs that have been increasingly used in the prevention and treatment of thromboembolic states. According to the mechanism of anticoagulant action, DOACs are divided into two groups: direct inhibitors of thrombin (dabigatran) and direct inhibitors of activated factor X (FXa) (rivaroxaban, apixaban, edoxaban, betrixaban). Compared to the vitamin K antagonists, DOACs are superior in terms of onset of action, pharmacokinetic and pharmacodynamics properties and fixed daily dose without the need for routine coagulation monitoring. Despite these advantages, there are clinical conditions in which laboratory measurement of DOACs should be performed. Although DOACs have an impact on screening haemostasis assays (prothrombin time, PT; activated partial thromboplastin time, aPTT; and thrombin time, TT), these tests are not appropriate for quantifying drug levels. Therefore, specific quantitative methods (LC-MS/MS as a gold standard method for all DOACs, coagulometric and chromogenic assays for dabigatran, and chromogenic anti-Xa assays with drug-specific calibrators for inhibitors of FXa) should only be used for determination of DOACs concentration. The aim of this review is to present all aspects of laboratory assessment of DOACs, including pre-analytical, analytical and post-analytical factors in the overall testing process with a special accent on the available specific quantitative methods for measurement of DOACs in circulation.
Subject
Pharmaceutical Science,Pharmacology,General Medicine
Reference91 articles.
1. 1. J. Carré, G. Jourdi, N. Gendron, D. Helley, P. Gaussem and L. Darnige, Recent advances in anticoagulant treatment of immune thrombosis: A focus on direct oral anticoagulants in heparin-induced thrombocytopenia and anti-phospholipid syndrome, Int. J. Mol. Sci. 23(1) (2022) Article ID 93; https://doi.org/10.3390/ijms23010093
2. 2. T. Helin, Laboratory Monitoring of Direct Oral Anticoagulants (PhD thesis), University of Helsinki, Medical Faculty, Helsinki 2017.
3. 3. J. W. Skelley, A. R. Thomason and J. C. Nolen, Betrixaban (Bevyxxa): A direct-acting oral anticoagulant factor Xa inhibitor, Pharm. Ther. 43(2) (2018) 85–120.
4. 4. C. Dunois, Laboratory monitoring of direct oral anticoagulants (DOACs), Biomedicines 9 (2021) Article ID 445 (15 pages); https://doi.org/10.3390/biomedicines9050445
5. 5. B. I. Eriksson, O. E. Dahl, L. Ahnfelt, P. Kälebo, J. Stangier, G. Nehmiz, K. Hermansson and V. Kohlbrenner, Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I, J. Thromb. Haemost. 2(9) (2004) 1573–1580; https://doi.org/10.1111/j.1538-7836.2004.00890.x
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献